摘要
【目的】探讨肝细胞肝癌(HCC)患者选用敏感化疗药物行肝癌经导管动脉灌注化疗栓塞术(TACE)治疗前后血清甲胎蛋白(AFP)、细胞间黏附分子-1(ICAM-1)水平的变化。【方法】采用化学发光免疫分析和酶联免疫法(ELISA)测定了30例HCC患者TACE治疗前后血清AFP、ICAM-1水平的变化,并与36名正常健康人作比较。【结果】TACE治疗前后HCC患者血清AFP、ICAM-1水平均非常显著地高于正常健康人(P均<0.01),TACE治疗后血清AFP、ICAM-1含量明显下降(P<0.01)。【结论】可根据药敏试验指导临床用药,血清AFP、ICAM-1水平对评价HCC患者行TACE治疗效果和观察病情具有一定的临床参考价值。
[Objective]To study the changes of serum alpha fetoprotein（AFP） and intercellular adhesion molecular-1（ICAM-1） levels in hepatocellular carcinoma（HCC） patients before and after treatment of transcatheter arterial chemoembolization（TACE） with sensitive chemotherapy drugs. [Methods]Serum AFP （with chemiluminescence immunoassay ） and ICAM-1 （with ELISA） levels were measured in 30 HCC patients both before and after treatment of TACE as well as in 36 controls. [Results]Before and after TACE treatment, serum AFP and ICAM-1 levels were significantly higher in the patients than those in controls （P〈0.01）, and the levels of AFP and ICAM-1 dropped obviously after TACE treatment（P〈0.01）. [Conclusion] Under the guidance of clinical drug susceptibility test,the detection of serum AFP and ICAM-1 is of clinical significance for the evaluation of therapeutic efficacy of TACE in HCC patients and observation of illness.
出处
《医学临床研究》
CAS
2008年第10期1755-1756,共2页
Journal of Clinical Research
基金
广西卫生厅资助项目(重200714
Z2007222)
关键词
癌
肝细胞/药物疗法
肝动脉
化学栓塞
治疗性
carcinoma, hepatocellular/DT
hepatic artery
chemoembolization, therapeutic
